Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use

Inflammatory Bowel Diseases

Volumn 14, Issue 8, 2008, Pages 1168-1170

  Danese, Silvio ^a   Mocciaro, Filippo ^b   Guidi, Luisa ^c,d   Scribano, Maria Lia ^e   Comberlato, Michele ^f   Annese, Vito ^g   Colombo, Elisabetta ^g   Stefanelli, Tommaso ^a   Marzo, Manuela ^c   Vangeli, Marcello ^h   Pulitano, Raffaella ⁱ   Manca, Aldo ⁱ   Armuzzi, Alessandro ^c   Malesci, Alberto ^a   Prantera, Cosimo ^e   Cottone, Mario ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d Complesso Integrato Columbus ^*  (Italy)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f Ospedale di Bolzano   (Italy)

^g CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^h OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁱ Gastroenterology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

ALLERGIC REACTION; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; LETTER; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; POLYETHYLENE GLYCOLS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 49749148697     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20426     Document Type: Letter

References (6)

1. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006;12:4807-4812.
2. Danese S, Pagano N, Angelucci E, et al. Tumor necrosis factor-alpha monoclonal anti-bodies for Crohn's disease: tipping the balance. Curr Med Chem. 2007;14:1489-1497.
3. Rutgeerts, P., G. Van Assche, and S. Venneire. 2006. Review article: Infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 23:451-463.
4. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238.
5. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.
6. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146:829-838.